Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: A randomized controlled trial

Journal of Nutritional Biochemistry

Volumn 25, Issue 2, 2014, Pages 144-150

  Chuengsamarn, Somlak ^a   Rattanamongkolgul, Suthee ^a   Phonrat, Benjaluck ^b   Tungtrongchitr, Rungsunn ^b   Jirawatnotai, Siwanon ^c  

^a SRINAKHARINWIROT UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Abdominal obesity (visceral fat and total body fat); Atherogenic risk; Curcuminoid extract; Insulin resistance; Pulse wave velocity (PWV); Type 2 diabetes

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; CURCUMIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID;

ABDOMINAL OBESITY; ADULT; ARTICLE; ATHEROSCLEROSIS; BODY FAT; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FASTING PLASMA GLUCOSE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HOT FLUSH; HUMAN; INSULIN RESISTANCE; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MIDDLE AGED; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; PROTEIN BLOOD LEVEL; PRURITUS; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; VERTIGO; WAIST CIRCUMFERENCE;

ABDOMINAL OBESITY (VISCERAL FAT AND TOTAL BODY FAT); ATHEROGENIC RISK; CURCUMINOID EXTRACT; INSULIN RESISTANCE; PULSE WAVE VELOCITY (PWV); TYPE 2 DIABETES;

ATHEROSCLEROSIS; CURCUMIN; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PLACEBOS;

EID: 84892527914     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2013.09.013     Document Type: Article

References (46)

1. Donnelly R., Davis K.R. Type 2 diabetes and atherosclerosis. Diabetes Obes Metab 2000, 2(Suppl 1):S21-S30.
2. Kannel W.B., McGee D.L. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979, 241:2035-2038.
3. Marfella R., Di Filippo C., D'Amico M., Paolisso G. Diabetes, ubiquitin proteasome system and atherosclerotic plaque rupture. Circ Res 2007, 100:e84-e85.
4. Calle M.C., Fernandez M.L. Inflammation and type 2 diabetes. Diabetes Metab 2012, 38:183-191.
5. Mazzone T., Chait A., Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 2008, 371:1800-1809.
6. Satoh N., Naruse M., Usui T., Tagami T., Suganami T., Yamada K., et al. Leptin-to-adiponectin ratio as a potential atherogenic index in obese type 2 diabetic patients. Diabetes Care 2004, 27:2488-2490.
7. Karakas M., Zierer A., Herder C., Baumert J., Meisinger C., Koenig W., et al. Leptin, adiponectin, their ratio and risk of Coronary Heart Disease: results from the MONICA/KORA Augsburg Study 1984-2002. Atherosclerosis 2010, 209:220-225.
8. Kotani K., Sakane N., Saiga K., Kurozawa Y. Leptin: adiponectin ratio as an atherosclerotic index in patients with type 2 diabetes: relationship of the index to carotid intima-media thickness. Diabetologia 2005, 48:2684-2686.
9. Lyon C.J., Law R.E., Hsueh W.A. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 2003, 144:2195-2200.
10. Rothenbacher D., Brenner H., Marz W., Koenig W. Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. Eur Heart J 2005, 26:1640-1646.
11. Reilly M.P., Iqbal N., Schutta M., Wolfe M.L., Scally M., Localio A.R., et al. Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J Clin Endocrinol Metab 2004, 89:3872-3878.
12. Ohman M.K., Shen Y., Obimba C.I., Wright A.P., Warnock M., Lawrence D.A., et al. Visceral adipose tissue inflammation accelerates atherosclerosis in apolipoprotein E-deficient mice. Circulation 2008, 117:798-805.
13. Miyawaki T., Abe M., Yahata K., Kajiyama N., Katsuma H., Saito N. Contribution of visceral fat accumulation to the risk factors for atherosclerosis in non-obese Japanese. Intern Med 2004, 43:1138-1144.
14. Dean B.B., Borenstein J.E., Henning J.M., Knight K., Merz C.N. Can change in high-density lipoprotein cholesterol levels reduce cardiovascular risk?. Am Heart J 2004, 147:966-976.
15. Grundy S.M. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 1998, 81:18B-25B.
16. Ishizaka N., Ishizaka Y., Toda E., Nagai R., Yamakado M. Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arterioscler Thromb Vasc Biol 2005, 25:1038-1044.
17. Nieto F.J., Iribarren C., Gross M.D., Comstock G.W., Cutler R.G. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis?. Atherosclerosis 2000, 148:131-139.
18. Kochhar K.P. Dietary spices in health and diseases (II). Indian J Physiol Pharmacol 2008, 52:327-354.
19. Jang E.M., Choi M.S., Jung U.J., Kim M.J., Kim H.J., Jeon S.M., et al. Beneficial effects of curcumin on hyperlipidemia and insulin resistance in high-fat-fed hamsters. Metabolism 2008, 57:1576-1583.
20. Ejaz A., Wu D., Kwan P., Meydani M. Curcumin inhibits adipogenesis in 3 T3-L1 adipocytes and angiogenesis and obesity in C57/BL mice. J Nutr 2009, 139:919-925.
21. Weisberg S.P., Leibel R., Tortoriello D.V. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology 2008, 149:3549-3558.
22. Asai A., Miyazawa T. Dietary curcuminoids prevent high-fat diet-induced lipid accumulation in rat liver and epididymal adipose tissue. J Nutr 2001, 131:2932-2935.
23. Seo K.I., Choi M.S., Jung U.J., Kim H.J., Yeo J., Jeon S.M., et al. Effect of curcumin supplementation on blood glucose, plasma insulin, and glucose homeostasis related enzyme activities in diabetic db/db mice. Mol Nutr Food Res 2008, 52:995-1004.
24. Baum L., Cheung S.K., Mok V.C., Lam L.C., Leung V.P., Hui E., et al. Curcumin effects on blood lipid profile in a 6-month human study. Pharmacol Res 2007, 56:509-514.
25. Singh S., Aggarwal B.B. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem 1995, 270:24995-25000.
26. Quiles J.L., Mesa M.D., Ramirez-Tortosa C.L., Aguilera C.M., Battino M., Gil A., et al. Curcuma longa extract supplementation reduces oxidative stress and attenuates aortic fatty streak development in rabbits. Arterioscler Thromb Vasc Biol 2002, 22:1225-1231.
27. Ramirez-Bosca A., Soler A., Carrion M.A., Diaz-Alperi J., Bernd A., Quintanilla C., et al. An hydroalcoholic extract of Curcuma longa lowers the apo B/apo A ratio. Implications for atherogenesis prevention. Mech Ageing Dev 2000, 119:41-47.
28. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009, 32:1327-1334.
29. Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med 2003, 9:161-168.
30. Schulz K.F., Altman D.G., Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMC Med 2010, 8:18.
31. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
32. Kushner R.F. Bioelectrical impedance analysis: a review of principles and applications. J Am Coll Nutr 1992, 11:199-209.
33. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
34. Katz A., Nambi S.S., Mather K., Baron A.D., Follmann D.A., Sullivan G., et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000, 85:2402-2410.
35. Nichols W.W. Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. Am J Hypertens 2005, 18:3S-10S.
36. Cruickshank K., Riste L., Anderson S.G., Wright J.S., Dunn G., Gosling R.G. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function?. Circulation 2002, 106:2085-2090.
37. Yamashina A., Tomiyama H., Arai T., Hirose K., Koji Y., Hirayama Y., et al. Brachial-ankle pulse wave velocity as a marker of atherosclerotic vascular damage and cardiovascular risk. Hypertens Res 2003, 26:615-622.
38. Satoh H., Kishi R., Tsutsui H. Metabolic syndrome is a significant and independent risk factor for increased arterial stiffness in Japanese subjects. Hypertens Res 2009, 32:1067-1071.
39. Satoh N., Ogawa Y., Usui T., Tagami T., Kono S., Uesugi H., et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003, 26:2493-2499.
40. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25:1105-1187.
41. Woolam G.L., Schnur P.L., Vallbona C., Hoff H.E. The pulse wave velocity as an early indicator of atherosclerosis in diabetic subjects. Circulation 1962, 25:533-539.
42. Tang Y., Zheng S., Chen A. Curcumin eliminates leptin's effects on hepatic stellate cell activation via interrupting leptin signaling. Endocrinology 2009, 150:3011-3020.
43. Martin S.S., Qasim A., Reilly M.P. Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol 2008, 52:1201-1210.
44. Goldstein B.J., Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 2004, 89:2563-2568.
45. Fruehwald-Schultes B., Peters A., Kern W., Beyer J., Pfutzner A. Serum leptin is associated with serum uric acid concentrations in humans. Metabolism 1999, 48:677-680.
46. Lin M.C., Nahin R., Gershwin M.E., Longhurst J.C., Wu K.K. State of complementary and alternative medicine in cardiovascular, lung, and blood research: executive summary of a workshop. Circulation 2001, 103:2038-2041.